Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
about
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitusOmega-3 supplements and cardiovascular diseasesIcosapent ethyl for the treatment of severe hypertriglyceridemia.Overview of prescription omega-3 fatty acid products for hypertriglyceridemiaGlobal metabolomic profiling reveals an association of metal fume exposure and plasma unsaturated fatty acidsA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsGene-diet interactions with polymorphisms of the MGLL gene on plasma low-density lipoprotein cholesterol and size following an omega-3 polyunsaturated fatty acid supplementation: a clinical trial.Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trialEffect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acidsA protective lipidomic biosignature associated with a balanced omega-6/omega-3 ratio in fat-1 transgenic miceLowering triglycerides to modify cardiovascular risk: will icosapent deliver?Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.Synthesis of enantiopure reversed structured ether lipids of the 1-O-alkyl-sn-2,3-diacylglycerol type.Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects.Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialDose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Omega-3 fatty acid supplementation and cardiovascular disease.Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.Acute appearance of fatty acids in human plasma--a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young malesEffects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyThe effects of herring-roe lyophilized powder on lipid metabolism.Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.Omega-3 polyunsaturated fatty acid profiles and relationship with cardiometabolic risk factors in Cree (Eeyouch) of Northern Québec.Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice.Interactions between Obesity Status and Dietary Intake of Monounsaturated and Polyunsaturated Oils on Human Gut Microbiome Profiles in the Canola Oil Multicenter Intervention Trial (COMIT).The Heart and Medicine: Exploring the Interconnectedness of Cardiometabolic-related Concerns Through a Systems Biology ApproachEffect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.Overview of omega-3 Fatty Acid therapiesPrescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers.A stable isotope biomarker of marine food intake captures associations between n-3 fatty acid intake and chronic disease risk in a Yup'ik study population, and detects new associations with blood pressure and adiponectin.Effects of supplementing n-3 fatty acid enriched eggs and walnuts on cardiovascular disease risk markers in healthy free-living lacto-ovo-vegetarians: a randomized, crossover, free-living intervention study.Icosapent ethyl for the treatment of hypertriglyceridemia.Cardiometabolic impact of non-statin lipid lowering therapies.Polyunsaturated fatty acids in emerging psychosis: a safer alternative?Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
P2860
Q26738554-6CF57FEF-8F7E-4311-B938-E44E09D37577Q26752919-41F258AB-452D-44F8-B2AD-EC05692C81B3Q26864908-95A39AC9-3972-4965-BADF-93FDEF215BEEQ27686834-7E970606-77D6-48B6-BEAE-5013DA07A199Q28251391-E1605870-443F-4FE5-A494-08FDDA7AD12DQ28389731-AE9DBD12-2411-4116-AB6A-7AA27362D0F3Q28972330-E0D796C6-8A47-434A-B66F-9B7EF7806F90Q33694013-11B2A6CA-6FC1-4AF8-9FC7-E7AE182E2F17Q34106302-DE77314E-F43B-4542-B42C-475B80523596Q34451932-CFD37298-6A77-45BF-BD84-30ABDE0CD8ADQ35034713-AEFE1818-E3C9-4D5A-B2B4-ED470AA3A296Q35156337-05726E09-D07E-4CB1-A040-43801792EBA7Q35230819-3001F31B-99D2-471B-886B-CD321C778880Q35460381-B5269884-6BD2-4F6A-B50B-20936A4654E1Q35540829-FFA07F44-0F8E-4350-9DE7-4C2E6CF4FA62Q35741991-2CC23656-F83E-4F2C-9BC0-02BD298C7560Q36012382-9B6E753A-F123-45AC-AC10-2A5318297711Q36019971-F8C69E3B-670F-4446-B17F-E15EAB9C8A09Q36368459-D1CB75E0-0664-46EF-8CBA-51473FAD3317Q36387184-54C2DB26-ADCC-49B5-8CAD-55F6112E4DA1Q36712679-33F0A38D-933E-4546-B108-F9CB6070A915Q37033572-8AAD83C8-DDE8-43BC-9268-C13DFEDBEFCDQ37033651-A39F8315-93CB-4278-BB95-E49C88108E3EQ37074741-A563D73F-9911-4E26-A342-794127B93BE7Q37099337-BC555EEB-B1C4-43CA-A1B5-2A909123DCF8Q37101182-03D4033F-2D1B-4AF2-988A-39BF5901997BQ37118744-2E7B724D-BB72-417A-9363-F32425CE4885Q37287426-A177EC60-9B01-466C-A863-3545CDD91C91Q37323347-1FCE033B-5062-416A-A376-F418350D3FA9Q37323846-CBED6BC1-76C4-4F3D-894E-C0E6BF069791Q37334006-60537655-BF04-4FD1-852B-4BAD2D9684CAQ37419411-E372F14D-49DA-4254-AC29-86CE5B6A101CQ37615904-17F87AE0-F185-4402-A4BB-F52BBCEB1B7AQ37626547-E3FC982A-FD51-4315-90B2-4B704B536667Q37701530-483A12BE-5B1A-479A-9273-F1E10E7A1E6AQ37725720-800453A6-BAB0-4BD5-94A3-CD175E9D2F14Q38108834-8CC79CAD-A425-40FB-9E76-F9AD70BFA8D8Q38176275-310010D0-52B1-4DF0-8E96-F52B0307BBC3Q38214798-BA729DC6-DF08-4910-89C7-27CCF11BA8A2Q38236677-4783BB0B-A863-4C25-AF57-DB82DCC389EA
P2860
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@en
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@nl
type
label
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@en
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@nl
prefLabel
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@en
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@nl
P2093
P1476
Effects of eicosapentaenoic ac ...... ol and other lipids: a review.
@en
P2093
Jonathan D Rowe
Paresh N Soni
Sara B Glickstein
Terry A Jacobson
P356
10.1016/J.JACL.2011.10.018
P407
P577
2011-11-03T00:00:00Z